No alternative for Phosphagenics

By Dylan Bushell-Embling
Wednesday, 24 September, 2008

Phosphagenics (ASX: POH) will cease trading on the Alternative Investment Market (AIM) of the British stock exchange.

According to Phosphagenics, monthly turnover of the company's AIM shares has decreased since listing four years ago, whereas turnover on the company's ASX shares have increased.

The Melbourne company has begun a Phase I clinical trial of its patented delivery system, TPM, for the topical delivery of the pain relief drug lidocaine.

The trial is being conducted at the Centre for Pharmaceutical Research at the University of South Australia.

The company expects early results in the first quarter of 2009.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd